H5N1 News and Research

Latest H5N1 News and Research

Yearlong moratorium on H5N1 research soon lifted, new rules implemented, Science reports

"U.S. government officials say they expect to put the finishing touches this month on new rules designed to help funding agencies identify and regulate especially problematic H5N1 studies before they begin," which would allow influenza researchers "to lift a year-old, self-imposed moratorium on certain kinds of potentially dangerous experiments," Science reports.

7 Jan 2013

NanoViricides to advance influenza drug candidate with completed $5M funding

NanoViricides, Inc., announced today that it has received the final tranche of $2.5M from Seaside 88, LP, thereby completing the total of a $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on June 29, 2012.

25 Dec 2012

Voluntary moratorium on H5N1 avian flu research likely to end soon

Following the conclusion of a two-day meeting at the National Institutes of Health (NIH) this week -- meant "to gather feedback from flu researchers, others in the science community, and the public on its draft framework for funding H5N1 gain-of-function studies and to continue an international dialogue on issues related to benefits and risks of the research" -- "experts anticipated that a voluntary moratorium on work with lab-modified strains that have increased transmissibility might end soon," CIDRAP News reports.

21 Dec 2012

Researchers report seroprevalence of three avian flu virus strains in pigs in southern China

Researchers report for the first time the seroprevalence of three strains of avian influenza viruses in pigs in southern China, but not the H5N1 avian influenza virus. Their research, published online ahead of print in the Journal of Clinical Microbiology, has implications for efforts to protect the public health from pandemics.

20 Dec 2012

Meeting participants discuss HHS framework for funding H5N1 avian influenza research

CIDRAP News reports on a two-day meeting at the National Institutes of Health during which "researchers, biosecurity experts, and others" discussed the "crafting of a framework for funding H5N1 avian influenza gain-of-function studies." The meeting "is the latest chapter in an intense scientific controversy that was triggered by the publication of two recent studies involving lab-engineered H5N1 strains that showed signs of being transmissible in mammals," according to the news service.

19 Dec 2012

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2012.

14 Dec 2012

U.S. government's draft guidance on funding for H5N1 research receives 'mixed reception,' Science reports

"Researchers are giving a mixed reception to a draft U.S. government plan to do more stringent funding reviews of certain kinds of H5N1 avian influenza research -- and perhaps even require some studies to be kept secret," Science reports.

8 Dec 2012

CEL-SCI's Multikine cancer drug receives key Japanese patent

CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).

29 Nov 2012

Parainfluenza virus 5 may serve as foundation for next breakthrough in human vaccine development

Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.

28 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Single dose of Medicago's vaccine could offer cross-protection against flu

Researchers recently found that a single dose of a vaccine being developed by Medicago, Inc., a publicly traded biopharmaceutical company, could protect against not only the avian influenza (H5N1) strain it was designed for, but also another H5N1 strain and a strain of a different flu subtype, called H2N2.

22 Nov 2012

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax's single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta.

15 Nov 2012

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.

23 Oct 2012

Significant increase in genomic Replikin Count of human SARS virus

The identification of the virus responsible for a second case of SARS-like respiratory virus, "London1_novel CoV 2012", has raised concerns over the risk of the disease spreading. These concerns may be justified given the observed rise in virus's genomic Replikin Count.

6 Oct 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Climate change associated with increased risk of avian flu transmission in wild birds

Rising sea levels, melting glaciers, more intense rainstorms and more frequent heat waves are among the planetary woes that may come to mind when climate change is mentioned. Now, two University of Michigan researchers say an increased risk of avian influenza transmission in wild birds can be added to the list.

30 Aug 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

16 Aug 2012

Orally effective FluCide anti-influenza drug candidate

NanoViricides, Inc. announced today that an anti-influenza drug candidate under its FluCide program is effective when given orally. The Company has received information that a FluCide drug candidate designed for oral administration has shown very strong efficacy in corresponding animal studies.

13 Aug 2012

H5N1 News and Research

Latest H5N1 News and Research

Yearlong moratorium on H5N1 research soon lifted, new rules implemented, Science reports

NanoViricides to advance influenza drug candidate with completed $5M funding

Voluntary moratorium on H5N1 avian flu research likely to end soon

Researchers report seroprevalence of three avian flu virus strains in pigs in southern China

Meeting participants discuss HHS framework for funding H5N1 avian influenza research

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

U.S. government's draft guidance on funding for H5N1 research receives 'mixed reception,' Science reports

CEL-SCI's Multikine cancer drug receives key Japanese patent

Parainfluenza virus 5 may serve as foundation for next breakthrough in human vaccine development

mRNA vaccines offer protection against influenza A virus infections in various animal models

Single dose of Medicago's vaccine could offer cross-protection against flu

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

Significant increase in genomic Replikin Count of human SARS virus

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

Strong antiviral antibody response observed in oral administration of Flucide

Climate change associated with increased risk of avian flu transmission in wild birds

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

Orally effective FluCide anti-influenza drug candidate

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

H5N1 News and Research

Latest H5N1 News and Research

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Newsletters you may be interested in